FDA approves Sun Pharma’s JAK inhibitor for alopecia
Sun Pharmaceutical Industries has secured the US Food and Drug Administration (FDA) approval for its oral Janus kinase (JAK) Inhibitor …
Sun Pharmaceutical Industries has secured the US Food and Drug Administration (FDA) approval for its oral Janus kinase (JAK) Inhibitor …
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended adjusting the marketing authorisation of Bavarian …
A parent’s worst nightmare is being told their child has been diagnosed with a rare disease. But being unable to …
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programmes and carry out a workforce …
Roche has reported a net income of SFr6.6bn ($7.4bn) in the first half (H1) of 2024, marking a 4% decline …
Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) …
AbbVie has announced its financial results for the second quarter (Q2) of 2024, revealing a 32.1% decrease in net earnings …
The European Commission (EC) has awarded conditional marketing authorisation for Pfizer's DURVEQTIX (fidanacogene elaparvovec), a one-time gene therapy for use …
AC Immune’s phosphorylated Tau (pTau)-targeting vaccine has secured a fast track designation from the US Food and Drug Administration (FDA) …
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day …
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including …
The US Food and Drug Administration (FDA) has granted ConSynance Therapeutics a rare paediatric disease designation for its oral therapy …
The US Food and Drug Administration (FDA) has expanded its approval of BioMarin Pharmaceutical's supplemental biologics licence application (sBLA) for …
The UK National Institute for Health and Care Excellence (NICE) has issued final guidance endorsing Boehringer Ingelheim’s tenecteplase, marketed as …
Dren Bio has partnered strategically with Novartis subsidiary Novartis Pharma to discover and develop therapeutic bispecific antibodies to treat cancer. The …